Doximity

The leading clinical AI company for medical professionals. Download the app today!

[Doximity @doximity]

After the visit is over, the prescription should be too.

Introducing Doximity Prescribe — free, fully mobile, and built into the platform physicians already use every day.

The Doximity Clinical AI Suite handles the visit, the note, and the clinical question. Now it handles the prescription too.

[HLTH @HLTHEVENT]

Félix Manuel Chinea of @Doximity shares why employers must rethink workplace wellbeing and create support systems that reflect the people they serve

🎥 Watch the session: https://t.co/By6KLpdRIp
🎫 Continue the conversation at #HLTHUSA: https://t.co/JrnOVCEl8q

#PrideMonth

[Doximity @doximity]

A standing ovation at #ASCO26.

That was the reaction when the Phase 3 RASolute-302 data for daraxonrasib were revealed.

Doximity interviewed Brian Wolpin, MD, about the results behind that moment: a randomized trial showing improved overall survival, progression-free survival, response rates, and quality of life compared with chemotherapy in previously treated metastatic pancreatic cancer.

In this conversation, he breaks down:
- How RAS inhibition is finally translating into clinical benefit
- Why these results are different from past efforts in pancreatic cancer
- What comes next, including first-line and adjuvant trials

[Doximity @doximity]

Learn more about RASolute-302 in Ask: https://t.co/Nab9jxDpV1

[Doximity @doximity]

A standing ovation at #ASCO26.

That was the reaction when the Phase 3 RASolute-302 data for daraxonrasib were revealed.

Doximity interviewed Brian Wolpin, MD, about the results behind that moment: a randomized trial showing improved overall survival, progression-free survival, response rates, and quality of life compared with chemotherapy in previously treated metastatic pancreatic cancer.

In this conversation, he breaks down:
- How RAS inhibition is finally translating into clinical benefit
- Why these results are different from past efforts in pancreatic cancer
- What comes next, including first-line and adjuvant trials

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

@doximity thank you for my daily breakfast donuts 🍩 this #ASCO26 forgot to get a Dox selfie 🤳 with @JeffTangney

[Doximity @doximity]

#ASCO26 is a wrap!

Great connecting with Oncologists this week and showing how tools like Doximity Ask and Scribe can streamline physician workflows.

[Doximity @doximity]

Last day of #ASCO26, did you know Doximity published an abstract on physician-reviewed AI clinical summaries? Stop by booth #30167 to learn more.

[Doximity @doximity]

Day 2 of #ASCO26 complete!

Join us for Day 3 at Booth #30167 to learn more about how oncologists are using Doximity Ask in practice!

[Doximity @doximity]

Full schedule → https://t.co/X5hCtVRkRb

[Doximity @doximity]

Day 1 at #ASCO26 ✅

So many oncologists joined our sessions today to talk AI in practice, and the excitement around Doximity Ask was incredible.

Back at Booth #30167 tomorrow. Don't miss it.

[Doximity @doximity]

We're at #ASCO26.

Find us at Booth #30167 throughout for live 15-minute AI workshops, Doximity's latest features, and coffee + donuts.

🧵 For our featured speakers!

[Doximity @doximity]

RT @DCockrellMD: Come by the @doximity booth tomorrow at 1:15p where I’ll be presenting on using their #AI tool (Doximity Ask) for assistan…

[Doximity @doximity]

@pshah_88 @DCockrellMD Full schedule here: https://t.co/X5hCtVRkRb

[Doximity @doximity]

We're at #ASCO26.

Find us at Booth #30167 throughout for live 15-minute AI workshops, Doximity's latest features, and coffee + donuts.

🧵 For our featured speakers!

[Doximity @doximity]

@pshah_88 Featuring:
Dillon Cockrell, MD (@DCockrellMD)
AI for immunotherapy and toxicity management on-call.
Saturday, May 30 | 1:15–1:30 PM CDT
#ASCO26

[Doximity @doximity]

New in Ask: get the peer-reviewed drug monograph the moment a medication appears in your query — so the dosing call is yours.